Brief: Revive Therapeutics Provides Update On FDA Phase 3 Clinical Trial For Bucillamine In Covid-19 With Plans On Emergency Use Access
23/12/2020 14:10
Dec 23 (Reuters) - Revive Therapeutics Ltd RVV.CD :
* REVIVE THERAPEUTICS PROVIDES UPDATE ON FDA PHASE 3
CLINICAL
TRIAL FOR BUCILLAMINE IN COVID-19 WITH PLANS ON EMERGENCY USE
ACCESS
* REVIVE THERAPEUTICS - ON PACE TO MEET ITS ENROLLMENT GOALS
FOR
INDEPENDENT DSMB TO REVIEW SAFETY,EFFICACY DATA FROM 210
PATIENTS
Source text for Eikon: ID:nGNX8dtqLg
Further company coverage: RVV.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure